TABLE 2.
Checklist of Information for Population Pharmacokinetic Studies*
| Model Reference and Items | Alfaro et al61 | Bez et al59 | Jiménez-Fernández et al63 | Kumra et al7 | Piscitelli et al62 | Schulz et al58 | Wohkittel et al60 | Item Compliance Rate (%) |
| Title/abstract | ||||||||
| Drug and patient population |
|
|
|
|
|
|
|
100 |
| Name of the drug(s) studied |
|
|
|
|
|
|
|
100 |
| Route of administration |
|
|
|
|
|
|
|
0 |
| Population studied |
|
|
|
|
|
|
|
100 |
| Primary objective |
|
|
|
|
|
|
|
85.7 |
| Major findings |
|
|
|
|
|
|
|
71.4 |
| Background | ||||||||
| Pharmacokinetic data |
|
|
|
|
|
|
|
0 |
| Study rationale |
|
|
|
|
|
|
|
85.7 |
| Special objectives/hypotheses |
|
|
|
|
|
|
|
71.4 |
| Discussion/conclusion | ||||||||
| Study limitations |
|
|
|
|
|
|
|
42.9 |
| Study findings |
|
|
|
|
|
|
|
100 |
| Study compliance rate (%) | 8/11 72.7 |
5/11 45.5 |
5/11 45.5 |
9/11 81.8 |
9/11 81.8 |
8/11 72.7 |
9/11 81.8 |
Following the recommendations of the study in Clinical Pharmacokinetics by Kanji et al53